Press Releases

Dec 22, 2020 10:12am EST

Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock

Dec 18, 2020 6:00am EST

Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock

Dec 15, 2020 6:00am EST

Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates

Dec 11, 2020 6:00am EST

Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer

Dec 09, 2020 9:05am EST

Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer

Dec 03, 2020 7:00am EST

Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space

Dec 02, 2020 7:00am EST

Greenwich LifeSciences to Present at the Annual LD Micro Main Event

Nov 23, 2020 7:00am EST

Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer

Nov 18, 2020 7:00am EST

Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2, Its Lead Drug Candidate for the Prevention of Recurring Breast Cancer

Nov 12, 2020 9:00am EST

Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial